MedTrace Logo

The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man

NCT01957098 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-10-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of L-arabinose and D-xylose in a sugar-rich drink on intestinal sucrase activity in healthy volunteers by measuring postprandial blood glucose and insulin, and selected intestinal hormonal responses to increasing doses of L-arabinose and D-xylose.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo comparator: 0% pentose

14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours

DIETARY_SUPPLEMENT

Active comparator: 4% D-xylose

DIETARY_SUPPLEMENT

Active comparator: 8% D-xylose

DIETARY_SUPPLEMENT

Active comparator: 8% L-arabinose

Sponsors & Collaborators

  • Danisco

    collaborator INDUSTRY

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Jens R Andersen, MD,MPA · Department of Nutrition, Exercise and sports, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-01-31
Completion
2007-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01957098 on ClinicalTrials.gov